195 related articles for article (PubMed ID: 38526540)
21. Options for Second-Line Treatment in Metastatic Colorectal Cancer.
Lee JJ; Sun W
Clin Adv Hematol Oncol; 2016 Jan; 14(1):46-54. PubMed ID: 27057668
[TBL] [Abstract][Full Text] [Related]
22. Ongoing and future directions in the management of metastatic colorectal cancer: Update on clinical trials.
Advani S; Kopetz S
J Surg Oncol; 2019 Apr; 119(5):642-652. PubMed ID: 30852840
[TBL] [Abstract][Full Text] [Related]
23. Colorectal cancer: how emerging molecular understanding affects treatment decisions.
Sridharan M; Hubbard JM; Grothey A
Oncology (Williston Park); 2014 Feb; 28(2):110-8. PubMed ID: 24701697
[TBL] [Abstract][Full Text] [Related]
24. Evidence-Based Second-Line Treatment in RAS Wild-Type/Mutated Metastatic Colorectal Cancer in the Precision Medicine Era.
Giordano G; Parcesepe P; Bruno G; Piscazzi A; Lizzi V; Remo A; Pancione M; D'Andrea MR; De Santis E; Coppola L; Pietrafesa M; Fersini A; Ambrosi A; Landriscina M
Int J Mol Sci; 2021 Jul; 22(14):. PubMed ID: 34299337
[TBL] [Abstract][Full Text] [Related]
25. A Comprehensive Review of Sequencing and Combination Strategies of Targeted Agents in Metastatic Colorectal Cancer.
Ciombor KK; Bekaii-Saab T
Oncologist; 2018 Jan; 23(1):25-34. PubMed ID: 29021377
[TBL] [Abstract][Full Text] [Related]
26. Long-term survivors of metastatic colorectal cancer treated with systemic chemotherapy alone: a North Central Cancer Treatment Group review of 3811 patients, N0144.
Dy GK; Hobday TJ; Nelson G; Windschitl HE; O'Connell MJ; Alberts SR; Goldberg RM; Nikcevich DA; Sargent DJ
Clin Colorectal Cancer; 2009 Apr; 8(2):88-93. PubMed ID: 19739269
[TBL] [Abstract][Full Text] [Related]
27. Precision medicine for metastatic colorectal cancer: an evolving era.
Guler I; Askan G; Klostergaard J; Sahin IH
Expert Rev Gastroenterol Hepatol; 2019 Oct; 13(10):919-931. PubMed ID: 31475851
[No Abstract] [Full Text] [Related]
28. Anti-metastatic treatment in colorectal cancer: targeting signaling pathways.
Lemos C; Sack U; Schmid F; Juneja M; Stein U
Curr Pharm Des; 2013; 19(5):841-63. PubMed ID: 22973955
[TBL] [Abstract][Full Text] [Related]
29. Metabolism, toxicity and management of fruquintinib: a novel drug for metastatic colorectal cancer.
Patell K; Mears VL; Storandt MH; Mahipal A
Expert Opin Drug Metab Toxicol; 2024 Apr; 20(4):197-205. PubMed ID: 38497279
[TBL] [Abstract][Full Text] [Related]
30. Safety and efficacy of nintedanib for the treatment of metastatic colorectal cancer.
Riesco-Martinez MC; Sanchez-Torre A; Garcia-Carbonero R
Expert Opin Investig Drugs; 2017 Nov; 26(11):1295-1305. PubMed ID: 28965421
[TBL] [Abstract][Full Text] [Related]
31. Rationally designed treatment for metastatic colorectal cancer: current drug development strategies.
Spiliopoulou P; Arkenau HT
World J Gastroenterol; 2014 Aug; 20(30):10288-95. PubMed ID: 25132745
[TBL] [Abstract][Full Text] [Related]
32. Prevalence of RAS mutations and individual variation patterns among patients with metastatic colorectal cancer: A pooled analysis of randomised controlled trials.
Peeters M; Kafatos G; Taylor A; Gastanaga VM; Oliner KS; Hechmati G; Terwey JH; van Krieken JH
Eur J Cancer; 2015 Sep; 51(13):1704-13. PubMed ID: 26049686
[TBL] [Abstract][Full Text] [Related]
33. Clinical management of metastatic colorectal cancer in the era of precision medicine.
Ciardiello F; Ciardiello D; Martini G; Napolitano S; Tabernero J; Cervantes A
CA Cancer J Clin; 2022 Jul; 72(4):372-401. PubMed ID: 35472088
[TBL] [Abstract][Full Text] [Related]
34. Molecular mechanisms targeting drug-resistance and metastasis in colorectal cancer: Updates and beyond.
Al Bitar S; El-Sabban M; Doughan S; Abou-Kheir W
World J Gastroenterol; 2023 Mar; 29(9):1395-1426. PubMed ID: 36998426
[TBL] [Abstract][Full Text] [Related]
35. Systemic Therapy for Metastatic Colorectal Cancer: From Current Standards to Future Molecular Targeted Approaches.
Atreya CE; Yaeger R; Chu E
Am Soc Clin Oncol Educ Book; 2017; 37():246-256. PubMed ID: 28561718
[TBL] [Abstract][Full Text] [Related]
36. Targeted therapy in colorectal cancer: current status and future challenges.
Koutras AK; Starakis I; Kyriakopoulou U; Katsaounis P; Nikolakopoulos A; Kalofonos HP
Curr Med Chem; 2011; 18(11):1599-612. PubMed ID: 21428886
[TBL] [Abstract][Full Text] [Related]
37. The role of miRNA -31-3p and miR-31-5p in the anti-EGFR treatment efficacy of wild-type K-RAS metastatic colorectal cancer. Is it really the next best thing in miRNAs?
Sur D; Cainap C; Burz C; Havasi A; Chis IC; Vlad C; Milosevic V; Balacescu O; Irimie A
J BUON; 2019; 24(5):1739-1746. PubMed ID: 31786833
[TBL] [Abstract][Full Text] [Related]
38. Targeted therapy for metastatic colorectal cancer: role of aflibercept.
Mitchell EP
Clin Colorectal Cancer; 2013 Jun; 12(2):73-85. PubMed ID: 23102896
[TBL] [Abstract][Full Text] [Related]
39. Addressing Resistance to Targeted Therapies in Metastatic Colorectal Cancer.
Jones J; Ciombor K; Wu C; Bekaii-Saab T; Strickler J
Oncology (Williston Park); 2021 Oct; 35(10):654-660. PubMed ID: 34677922
[TBL] [Abstract][Full Text] [Related]
40. Do cancer biomarkers make targeted therapies cost-effective? A systematic review in metastatic colorectal cancer.
Seo MK; Cairns J
PLoS One; 2018; 13(9):e0204496. PubMed ID: 30256829
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]